Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 November 2024, including: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH
J&J Psoriasis Pill In A Tier Of Its Own After Phase III Win
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors
China Dominates APAC’s Emergence As Global Trials Hub
Scrip M&A Podcast: Why Has M&A Activity Ramped Downward In 2024?